Cubist News The lastest news from Cubist 2014 Cubist 1440 iMarc flourish plugin fpORMRSS v1.0 en-US Mon, 01 Sep 2014 07:11:29 EDT How To Avert An Antibiotic Apocalypse Mon, 27 Jan 2014 12:00:00 EST Want to protect your kids from drug-resistant bacteria? Open your wallet. Governments and insurance companies need to commit to paying 10 or 50 times more than they already do if industry is going to put resources into fighting the threat of superbugs. Cubist Pharma on the Front Lines of Superbug War Mon, 16 Dec 2013 12:00:00 EST At Cubist Pharmaceuticals‘ labs in Lexington, Mass., researchers feel like they are in a race against time. They are trying to develop antibiotics to fight infections that are becoming increasingly untreatable and deadly. And they feel they are playing catch up with these superbugs. Watch the video: Cubist Pharma on the Front Lines of Superbug War Mon, 16 Dec 2013 12:00:00 EST Cubist Pharmaceutical CEO Michael Bonney talks to CNBC's Bertha Coombs about his company's big bet on antibiotics to treat superbugs, which recently drove the firm to acquire two smaller rivals. He leaves the door open to future deals. Hunting the Nightmare Bacteria: Who’s Trying to Fix the Pipeline Problem? Tue, 22 Oct 2013 12:00:00 EDT The problem is clear: There aren’t enough new antibiotics. The question is why aren’t more pharmaceutical companies filling the gap – and what’s being done to try to reverse this trend? Here’s How One Antibiotics Maker Finds Success Thu, 19 Sep 2013 12:00:00 EDT Bloomberg’s Olivia Sterns examines drugmaker Cubist and their ability to make a profit in antibiotics as other companies fall short. She speaks on Bloomberg Television’s “In The Loop.” Addressing the Unmet Need for Anti-Infective Development. Cubist feature in SciBX Collections on Antibiotic Resistance Sun, 01 Sep 2013 12:00:00 EDT Rising to the challenge of multidrug-resistant bacteria, Cubist is building a robust anti-infective development portfolio. Big Pharma Exit: Who's Fighting the Superbugs? Wed, 24 Apr 2013 12:00:00 EDT Cave Explorer Hunts Antibiotics 1,600 Feet Down: Health Wed, 27 Feb 2013 12:00:00 EST By teaming with Barton, Cubist is betting that drug discovery in nature, long abandoned by many other drugmakers, may hold a key to building its share of the global market for branded antibiotics, estimated at $9.5 billion in 2011, according to data compiled by Bloomberg Industries. “Most antibiotics in use today are derived from natural products,” Cubist Chief Executive Officer Michael Bonney said in an interview. “They are nature’s way of arming bacteria in the soil so it can protect its homeland.”